Heart failure
Conditions
Interventions
Intervention group:Withdrawal of pharmacological treatment for heart failure
Control group:Continuing pharmacological treatment of HF
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1: Age 18-80 years old 2: Catheter ablation of atrial fibrillation or atrial flutter 3 months ± 1 month ago 3: Patients with echocardiographic LVEF = 45% 12 months before catheter ablation, and those who can tolerate ablation with or without phamarcological treatment for heart failure 4: Taking guideline-directed medical therapy after ablation 5: Baseline echocardiographic LVEF = 55% and LVEDD within the normal range 6: Baseline NT-proBNP <250ng/L 7: Absence of current symptoms and signs of heart failure 8: Current treatment with a loop diuretic, ARNI/ACEI/ARB, beta-blocker, mineralocorticoid receptor antagonist (MRA), or SGLT2i, or a combination of these drugs 9: Informed and agree to participate in this study
Exclusion criteria
Exclusion criteria: 1: With other clearly diagnosed cardiomyopathy 2: Diagnosis of heart failure before the diagnosis of atrial fibrillation or atrial flutter 3: Atrial fibrillation, atrial flutter, or atrial tachycardia at 3 months ± 1 month after catheter ablation 4: With frequent premature ventricular contractions, ventricular tachycardia, atrioventricular or atrioventricular nodal reentry tachycardia 5: Imaging diagnosis of coronary heart disease 6: Uncontrolled hypertension (blood pressure >160/100 mm Hg) 7: Valvular disease of moderate or greater severity 8: Estimated glomerular filtration rate less than 30 mL/min per 1·73 m2 9: Planned heart surgery within 1 year 10: Pregnancy 11: Life expectancy < 1 year (such as malignant tumors, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse of heart failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Composite endpoint of cardiovascular death, non fatal stroke, non fatal myocardial infarction, and hospitalization due to heart failure;Ultrasound: LVEF, LVEDD;Changes of NT-pro-BNP concentration between baseline and follow-up;Changes of scores of Kansas City Cardiomyopathy Questionnaire;Atrial fibrillation burden;Adverse drug reactions;MRI: LVEF, LVEDVi, LAVi, T1 time;Resting heart rate;Systolic and diastolic blood pressure; | — |
Countries
China
Contacts
Public ContactCaihua Sang
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed